A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer

Clinical Breast Cancer

Volumn 13, Issue 2, 2013, Pages 81-87

  Petrelli, Fausto ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

HER2 positive; Metastatic breast cancer; Second line

Indexed keywords

TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG EFFICACY; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

EID: 84875148538     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.11.008     Document Type: Review

References (41)

1. D.J. Slamon, G.M. Clark, S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
2. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
3. D. Cameron, M. Casey, M. Press A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 2008 533 543
4. S. Verma, D. Miles, L. Gianni Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 2012 1783 1791
5. K.L. Blackwell, H.J. Burstein, A.M. Storniolo Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer J Clin Oncol 28 2010 1124 1130
6. J. Baselga, K.A. Gelmon, S. Verma Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy J Clin Oncol 28 2010 1138 1144
7. G. von Minckwitz, A. du Bois, M. Schmidt Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 2009 1999 2006
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf Accessed: July 10, 2012
9. C. Christodoulou, G. Klouvas, A. Pateli Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer Anticancer Res 23 2003 737 744
10. G. Fountzilas, E. Razis, D. Tsavdaridis Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group Clin Breast Cancer 4 2003 120 125
11. Y. Suzuki, Y. Tokuda, Y. Saito Combination of trastuzumab and vinorelbine in metastatic breast cancer Jpn J Clin Oncol 33 2003 514 517
12. K.A. Gelmon, J. Mackey, S. Verma Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories Clin Breast Cancer 5 2004 52 58
13. D. Tripathy, D.J. Slamon, M. Cobleigh Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 22 2004 1063 1070
14. J.A. García-Sáenz, M. Martín, J. Puente Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer Clin Breast Cancer 6 2005 325 329
15. H.J. Stemmler, S. Kahlert, W. Siekiera Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) Onkologie 28 2005 582 586
16. A. Morabito, R. Longo, D. Gattuso Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer Oncol Rep 16 2006 393 398
17. R. Bartsch, C. Wenzel, D. Hussian Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study BMC Cancer 6 2006 63
18. K. Furukawa, Y. Ito, S. Takahashi Efficacy and safety of combined trastuzumab and paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience Breast Cancer 13 2006 329 333
19. V. Adamo, T. Franchina, B. Adamo Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) Ann Oncol 18 Suppl 6 2007 vi11 vi15
20. R. Bartsch, C. Wenzel, G. Altorjai Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer J Clin Oncol 25 2007 3853 3858
21. R. Bartsch, C. Wenzel, S.P. Gampenrieder Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer Cancer Chemother Pharmacol 62 2008 903 910
22. F. Montemurro, S. Redana, G. Viale Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era Clin Breast Cancer 8 2008 436 442
23. G. Cancello, E. Montagna, D. D'Agostino Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer Breast Cancer Res 10 2008 R60
24. R. Bartsch, C. De Vries, U. Pluschnig Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer BMC Cancer 9 2009 367
25. H. Rugo, P. Kaufman, E. Tan-Chiu Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of registHER Cancer Res 69 Suppl S 2009 2
26. D.A. Yardley, H.A. Burris 3rd, S. Hanson Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer Clin Breast Cancer 9 2009 178 183
27. J.M. Extra, E.C. Antoine, A. Vincent-Salomon Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study Oncologist 15 2010 799 809
28. G. Metro, D. Giannarelli, D. Gemma Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer Breast J 16 2010 66 72
29. K. Inoue, K. Nakagami, M. Mizutani Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group Breast Cancer Res Treat 119 2010 127 136
30. T. Waddell, A. Kotsori, A. Constantinidou Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience Br J Cancer 104 2011 1675 1679
31. M. Campiglio, R. Bufalino, M. Sandri Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study Breast Cancer Res Treat 128 2011 147 154
32. J. Huober, M. Baumann, C. Rochlitz Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers Oncology 81 2011 160 166
33. M. Hayashi, Y. Okumura, T. Osako Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer Int J Clin Oncol 16 2011 694 700
34. G. von Minckwitz, K. Schwedler, M. Schmidt Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer Eur J Cancer 47 2011 2273 2281
35. X. Pivot, V. Semiglazov, B. Zurawski (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with Lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC) [Abstract] Ann Oncol 23 Suppl 9 2012 ixe2 LBA5-PR
36. A. Mannocci, E. De Feo, C. de Waure Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: a systematic review of published studies Tumori 96 2010 385 391
37. A. Fabi, G. Metro, G. Ferretti Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies Breast 17 2008 499 505
38. B. Kaufman, J.R. Mackey, M.R. Clemens Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 2009 5529 5537
39. M.A. Cobleigh, C.L. Vogel, D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648
40. Y.X. Shi, Y.T. Tan, Z.Y. Yuan Comparison of overall survival between the early use and delayed use of trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer Med Oncol 29 2012 39 47
41. Y.N. Wong, R.A. Ottesen, M.E. Hughes Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence? Oncologist 16 2011 559 565